KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other financing activities (2018 - 2025)

Sarepta Therapeutics (SRPT) has 9 years of Other financing activities data on record, last reported at $110000.0 in Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $110000.0; the TTM value through Dec 2025 reached $664000.0, up 19.86%, while the annual FY2025 figure was $2.4 million, N/A changed from the prior year.
  • Other financing activities reached $110000.0 in Q4 2025 per SRPT's latest filing, down from $554000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.4 million in Q2 2021 and bottomed at $110000.0 in Q4 2025.
  • Average Other financing activities over 3 years is $698666.7, with a median of $554000.0 recorded in 2022.